The massive overhang of ~22.3M shares (41.5% of outstanding) registered for immediate resale by sophisticated healthcare investors creates significant near-term selling pressure. Monitor for the effectiveness date of the S-3 and any subsequent 424B prospectus supplements that may indicate selling activity. The company's cash runway into 2028 reduces urgency for additional capital raises, but the registration allows existing holders to exit, which is likely to cap upside and pressure the stock.
Price Chart
Executive Summary
Whitehawk Therapeutics filed an S-3 registration statement to register 22,321,887 shares for resale by selling stockholders, consisting of 4,330,866 outstanding shares and 17,991,021 shares issuable upon exercise of pre-funded warrants. These shares were issued in a private placement on May 14, 2026 that raised approximately $87.5 million in gross proceeds for the company. The company will not receive any proceeds from the resale of shares under this prospectus, but would receive the nominal exercise price ($0.0001/share) if pre-funded warrants are exercised for cash.
Key Facts
- S-3 registers 22,321,887 shares for resale by selling stockholders from a private placement closed May 14, 2026
- Private placement raised ~$87.5 million total: 4,330,866 shares at $3.92/share and 17,991,021 pre-funded warrants at $3.9199/share with $0.0001 exercise price
- Shares registered represent ~41.5% of the 53,783,329 shares outstanding as of May 14, 2026
- Company will not receive proceeds from resales; only nominal proceeds from warrant exercises
- Registration rights agreement requires filing within 30 days and effectiveness within 60-90 days of closing
- Company is a clinical-stage oncology biotech with no current product revenue after divesting FYARRO business in March 2025
- Cash runway guided into 2028 based on existing cash, cash equivalents and short-term investments
- Cross-filing context includes a 10-Q filed May 7, 2026 (22 days prior) for financial position context
Financial Impact
Up to ~$101.3M in shares registered for resale at $4.54 reference price; ~41.5% dilution over current outstanding shares if all pre-funded warrants are exercised and shares sold
Risk Factors
- Significant dilution overhang with 41.5% of shares outstanding registered for resale
- Selling stockholders include major healthcare funds (Avoro, Suvretta, QVT, Coastlands) that may seek to exit positions
- Clinical-stage biotech with no current revenue and high cash burn rate for three Phase 1 ADC trials
- Pre-funded warrants have no expiration and can be exercised at any time, creating ongoing overhang uncertainty
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001193125-26-248349 |
| Document: d155546dex102.htm | 0001193125-26-248349 |
| Document: d155546dexfilingfees.htm | 0001193125-26-248349 |
| Document: d155546dex51.htm | 0001193125-26-248349 |
| Document: d155546dex231.htm | 0001193125-26-248349 |
| Document: 0001193125-26-248349-index-headers.html | 0001193125-26-248349 |
| Document: 0001193125-26-248349-index.html | 0001193125-26-248349 |
| Document: 0001193125-26-248349.txt | 0001193125-26-248349 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 6w ago | 8-K | $4.11 $4.07 | ▼ −0.97% | ▼ −0.53% | $3.32 (−19.22%) |
Aug 6, 2026 11w ago | 8-K | $4.70 $4.76 | ▲ +1.28% | ▲ +0.67% | $3.32 (−29.36%) |
Jun 10, 2026 19w ago | EFFECT | $4.02 $4.06 | ▼ −0.99% | ▲ +0.70% | $3.32 (+17.41%) |
May 29, 2026 21w ago | S-3 | $4.49 $4.18 | ▲ +6.90% | ▲ +7.06% | $3.32 (+26.06%) |
May 13, 2026 23w ago | 8-K | $4.93 $5.10 | ▼ −3.45% | ▼ −2.67% | $3.32 (+32.66%) |
May 7, 2026 24w ago | 8-K | $3.94 $3.97 | ▲ +0.76% | ▼ −0.07% | $3.32 (−15.74%) |
Apr 8, 2026 28w ago | Insider Cluster | $3.55 $3.39 | ▲ +4.51% | ▲ +4.45% | $3.32 (+6.48%) |
Apr 8, 2026 28w ago | Insider Cluster | $3.55 $3.39 | ▲ +4.51% | ▲ +4.45% | $3.32 (+6.48%) |
Apr 8, 2026 28w ago | Insider Cluster | $3.55 $3.39 | ▲ +4.51% | ▲ +4.45% | $3.32 (+6.48%) |
Mar 12, 2026 32w ago | 8-K | $3.90 $3.91 | ▲ +0.26% | ▲ +0.85% | $3.32 (−14.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers